Jan Hendrik Egberts
Jan has over 25 years of experience in the pharmaceutical and medtech industries, most recently as CEO at Agendia. Prior to this, he was CEO of OctoPlus, served as an advisor for 3i Group, and as President, Chairman and CEO of NovaDel Pharmaceuticals. In addition, Jan held multiple business development and general management positions at Johnson & Johnson, Merck and Mölnlycke. He graduated from Erasmus University Medical School in the Netherlands and obtained his MBA from Stanford, after which he worked as a management consultant for McKinsey. Jan continues to serve on the supervisory board of the Center for Human Drug Research (CHDR), Pharming Group, Lead Pharma and Implanet.